John Mascarenhas, MD, discusses the rationale, mechanism, and design of the phase 1 INCA33989-101 and -102 trials investigating a CAL-R–targeted antibody for patients with essential thrombocythemia.

Exposure to a common agricultural contaminant in drinking water, even in small doses, may be linked to increased risks of ...

A breakthrough clinical trial in Japan reveals that a vitamin B3 derivative significantly improves symptoms of the rare ...